Ceapro Awarded Research Contribution from NRC for Development, Demonstration and Testing of PGX
EDMONTON, ALBERTA - Ceapro Inc., an Edmonton based, growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced that the National Research Council of Canada (NRC) through its Industrial Research Assistance Program (IRAP) has made a contribution of up to $350,000 for the development, demonstration and testing of Ceapro's PGX technology.
The main objective of the grant is to support salaries of researchers dedicated to the building of a fully functional skid in Alberta for processing a wide range of feedstock using the PGX equipment. The implementation of PGX at a commercial and demonstration scale could potentially generate multiple novel bio-based products with improved purity and functionality and has the potential to impact the growth of the Canadian bio-industrial sector.